The U.S. and the Global Populations are aging. Ten percent of the general population suffers osteoarthritis, and 80% of people over 75 suffer. The top 20 therapies for OA are considered to be LESS THAN 60% EFFECTIVE.
Osteoarthritics therapeutics market is forecast to show slow growth until 2018. The current therapies offer only symptomatic relief. There are no disease modifying technologies approved NOR in late stage pipeline.
A product that can successfully help osteoarthritis patients has the potential for billion-dollar revenues.